GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » EBITDA Margin %

HMTXF (Hemostemix) EBITDA Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Hemostemix EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hemostemix's EBITDA for the three months ended in Sep. 2024 was $-0.63 Mil. Hemostemix's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Hemostemix's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.


Hemostemix EBITDA Margin % Historical Data

The historical data trend for Hemostemix's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemostemix EBITDA Margin % Chart

Hemostemix Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hemostemix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hemostemix's EBITDA Margin %

For the Biotechnology subindustry, Hemostemix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemostemix's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Hemostemix's EBITDA Margin % falls into.


;
;

Hemostemix EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Hemostemix's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-1.455/0
= %

Hemostemix's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.633/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemostemix  (OTCPK:HMTXF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Hemostemix EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Hemostemix's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemostemix Business Description

Traded in Other Exchanges
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.